1247003-58-2

Basic information

• Product Name: tert-butyl 4-(4-ethynylphenyl)piperazine-1-carboxylate
• Synonyms: tert-butyl 4-(4-ethynylphenyl)piperazine-1-carboxylate
• CAS NO: 1247003-58-2
• Molecular Weight: 286.374
• Mol File: 1247003-58-2.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: tert-butyl 4-(4-ethynylphenyl)piperazine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-(4-ethynylphenyl)piperazine-1-carboxylate(1247003-58-2)
• EPA Substance Registry System: tert-butyl 4-(4-ethynylphenyl)piperazine-1-carboxylate(1247003-58-2)

Safety Data

• Hazardous Substances Data: 1247003-58-2(Hazardous Substances Data)

Upstream product

• 151978-66-4 tert-butyl 4-(4-iodophenyl)tetrahydro-1(2H)-pyrazinecarboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 624726-35-8 1-(4-iodophenyl)piperazine hydrochloride 
• 90965-06-3 dimethyl 1-(1-diazo-2-oxopropyl)phosphonate 
• 197638-83-8 4-(4-(1,1-dimethylethoxycarbonyl)piperazinyl)benzaldehyde 

Downstream Products

• 1338806-32-8 (1R,2S)-(E)-2-(3-(4-(piperazin-1-yl)styryl)-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-one 2,2,2-trifluoroacetate 
• 1247003-59-3 (E)-tert-butyl 4-(4-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)vinyl)phenyl)piperazine-1-carboxylate 

Relevant articles and documents

Fragment-Based Drug Design Facilitated by Protein-Templated Click Chemistry: Fragment Linking and Optimization of Inhibitors of the Aspartic Protease Endothiapepsin

There is an urgent need for the development of efficient methodologies that accelerate drug discovery. We demonstrate that the strategic combination of fragment linking/optimization and protein-templated click chemistry is an efficient and powerful method that accelerates the hit-identification process for the aspartic protease endothiapepsin. The best binder, which inhibits endothiapepsin with an IC50value of 43 μm, represents the first example of triazole-based inhibitors of endothiapepsin. Our strategy could find application on a whole range of drug targets.

KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME

The invention is directed to a compound represented by the following structural formula pharmaceutically acceptable salts thereof: (I). Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.